Cingulate prepares for FDA approval for its once-daily ADHD pill
To that end, the company presented positive top-line Phase III results for its once-daily stimulant for ADHD.
Other Articles in this Edition
When it comes to adult ADHD, the US medical system is falling behind
Shortage of drugs to treat ADHD continues as studies indicate increase in prescriptions
What’s behind the ADHD drug shortage
Stimulant therapy for ADHD in teens doesn’t increase risk of cocaine or methamphetamine use later
Cingulate prepares for FDA approval for its once-daily ADHD pill
Individuals with ADHD have an increased risk of instability in various domains of life
Study looks for possible link between ADHD and Alzheimer’s disease
Genetic factors impacting birth weight and neurodivergence
Consuming THC during pregnancy could put unborn babies at higher risk of autism or ADHD
The Risks and Benefits of ADHD Medications While Pregnant